IngredientsInvertase, also known as β-fructofuranosidase (EC 3.2.1.26), is an enzyme that catalyzes the hydrolysis of sucrose into its constituent monosaccharides, glucose and fructose, by cleaving the α-1,2-glycosidic bond between them. The formal and systematic name of invertase is β-fructofuranosidase (EC 3.2.1.26), also termed sucrose glycosidase. Additional synonyms include fructosidase, d-fructofuranoside fructohydrolase, sucrase, invertin, and saccharase. It was originally called invertase due to the fact that when sucrose is hydrolysed, the optical rotation reverts from dextrorotatory to levorotatory.
This process produces an equimolar mixture known as invert sugar, which is sweeter and less prone to crystallization than sucrose. The CAS Registry number for invertase is 9001-57-4.
Invertase is an enzyme of the glycoside hydrolase family. The enzyme belongs to family GH32 of the sequence-based classification of glycosidases, with a crystal structure that reveals two modules, including a five-bladed β-propeller with structural similarity to β-propeller structures of glycosidase from related families. In Saccharomyces cerevisiae, invertase shows an unusual octameric quaternary structure composed of two types of dimers, and a peculiar pattern of monomer assembly through non-catalytic domain interactions determines invertase specificity.
Distinct from sucrase (EC 3.2.1.48) found in animals, which cleaves sucrose from the glucose side, invertase acts as a retaining β-fructosidase, employing a catalytic mechanism involving key residues such as aspartate and glutamate to facilitate the reaction without inverting the anomeric configuration of the fructose product.
Invertase possesses both hydrolytic and transfructosylating activity; it catalyzes the breakdown of the β-(1-2) linkage of sucrose and also transfers the fructosyl unit to sucrose. Some, but not all, invertase enzymes can act on short fructooligosaccharides such as 1-kestotriose, 1,1-kestotetraose, raffinose, and stachyose.
Invertase is produced by various organisms such as yeast, fungi, bacteria, higher plants, and animals; these include Saccharomyces cerevisiae, Saccharomyces carlsbergensis, S. pombe, Aspergillus spp., Penicillium chrysogenum, Azotobacter spp., Lactobacillus spp., and Pseudomonas spp. Yeast species such as Saccharomyces cerevisiae and Candida utilis are used for commercial production of invertase; of fungi, the filamentous fungi of the Aspergillus genus — particularly Aspergillus niger — are also used as commercial sources.
Invertase is involved in the digestion process in humans; it is released by the cells located in the mucous membrane of the small intestine. The honey bee enzyme responsible for sucrose hydrolysis is now classified as α-glucosidase (EC 3.2.1.20), distinct from yeast β-fructofuranosidase (EC 3.2.1.26), which is the enzyme currently recognized as invertase in biochemical nomenclature. Thus, while the popular literature often attributes honey bee invertase to EC 3.2.1.26, the two enzymes are biochemically distinct.
Invertase is widespread in microorganisms — present extracellularly in yeast Saccharomyces cerevisiae cell walls — as well as in plants (in cell walls, cytoplasm, and vacuoles), and bacteria (e.g., Thermotoga maritima), with microbial forms contributing to animal microbiomes, such as bacterial invertase in human saliva.
The temperature optimum for invertase activity is 60 °C and the pH optimum is 4.5. In contrast to many other body enzymes, invertase is very versatile in that it can remain active within different changes in pH levels.
For use in food and dietary supplements, invertase is available as a high-purity enzyme preparation. It is commercially available from Saccharomyces cerevisiae in both powder and liquid forms. The standard unit of activity used in the food supplement industry is the Sumner Unit (SU): one SU (Sumner Unit Invertase/Sucrase) is the FCC assay of measurement, whereby one Sumner Unit is the quantity of enzyme that will convert 1 mg of sucrose to glucose and fructose under defined conditions.
Invertase is used extensively in the preparation of jams, marshmallows, infant formulas, candies containing liquefied sugar centers, chocolate-covered cherries, digestive aid tablets, artificial honey, beverages, and bakery items. As a pharmaceutical-grade product, the FDA-approved oral solution sacrosidase (Sucraid) is a pale yellow to colorless, clear solution of glycerol, water, and citric acid; each milliliter of Sucraid contains 8,500 IU of the enzyme sacrosidase.
Invertase, the β-d-fructofuranosidase (EC 3.2.1.26), is one of the earliest discovered enzymes. For the first time, it was reported in 1842 by Mitscherlich that yeast contains a substance able to change dextrorotatory cane sugar into a levorotatory sugar. In 1847, this mixture was identified as glucose and fructose by Dubrunfaut. Berthelot, in 1860, during the attempt at recognizing enzyme activity during fermentation, succeeded in isolating invertase from yeast and published that extract from beer yeast is able to decompose sucrose into fructose and glucose.
Pasteur had thought that succinic acid inverted sucrose; in 1860, Marcellin Berthelot isolated invertase and showed that succinic acid did not invert sucrose. Pasteur believed that fermentation was only due to living cells, and he and Berthelot engaged in a long argument on the subject of vitalism, in which Berthelot was vehemently opposed to any idea of vitalism.
Invertase served as the model enzyme for the landmark kinetic studies by Michaelis and Menten (1913) and Briggs and Haldane (1926) that established the mathematical framework still used today to describe enzyme behavior; the Michaelis-Menten equation, fundamental to all enzyme kinetics, was developed using invertase data.
While invertase was not isolated and identified until the late 19th century, the process it catalyzes — sugar inversion — has been used for centuries in traditional sweet-making and brewing. Early confectioners unknowingly leveraged natural enzymatic or acid-based processes to create smoother syrups and soft centers in sweets and baked goods.
Traditionally, inverted sugar syrup was produced by adding acid to a concentrated sucrose solution. Enzymatically derived inverted sugar syrup, on the other hand, is an organic product and is considered a much cleaner product with better flavours and more desirable colors.
In modern enzymology, invertase became one of the most studied enzymes due to its clear mechanism and broad utility, serving as a model for understanding enzyme-substrate interactions and carbohydrate metabolism.
Though not typically part of traditional herbal medicine systems, invertase has gained importance in integrative digestive health, where it is combined with enzymes like amylase, lactase, cellulase, and lipase to provide comprehensive support for carbohydrate digestion and nutrient bioavailability.
The use of honey — a natural product of invertase-related enzymatic activity — in traditional medicine across many cultures is well-documented, though specific attributions to invertase itself are modern. Invertase is one of the essential enzymes in nature that helps us to break down sugars; it not only plays a crucial role in the sugar breakdown process, but also can help prevent human diseases, as seen in bee pollen.
Invertase catalyzes the hydrolysis of the disaccharide sucrose into its monosaccharide components, D-glucose and β-D-fructose. Sucrose, chemically α-D-glucopyranosyl-(1→2)-β-D-fructofuranoside, serves as the primary substrate, with the enzyme cleaving the glycosidic bond at the fructose moiety.
This specific invertase (β-fructofuranosidase) cleaves the molecule from its fructose end, resulting in the two monosaccharides. It does this by adding a hydrogen ion to the glycosidic atom by an imidazolium cation; from there, an unstable intermediate carbonium ion is formed by the departure of an alcohol group. Finally, the nucleophilic oxygen atom from alcohol or water attacks the C-2 cation, which leaves behind a fructose molecule. The active-site carboxylate anion helps keep the unequal balance of electrons stabilized throughout this process.
Invertase also possesses transfructosylating activity; it catalyzes the breakdown of the β-(1-2) linkage of sucrose and transfers the fructosyl unit to sucrose, with the fructooligosaccharides (FOS) produced by this method being 1-kestose (glucose-fructose₂), 1-nystose (glucose-fructose₃), and 1-fructosylnystose (glucose-fructose₄). At high sucrose concentrations, transfructosylation activity can account for a significant proportion of total enzyme activity.
Invertase helps the body efficiently digest sucrose, converting it into the highly bioavailable monosaccharides glucose and fructose, which supports the absorption of these essential nutrients in the small intestine. Sucrase is naturally produced in the brush border of the small intestine, primarily the distal duodenum and jejunum. Human starch digestion is a multi-enzyme process involving six different enzymes: salivary and pancreatic α-amylase; sucrase and isomaltase (from sucrase-isomaltase [SI]), and maltase and glucoamylase (from maltase-glucoamylase [MGAM]). Together these enzymes cleave starch to smaller molecules, ultimately resulting in the absorbable monosaccharide glucose. Approximately 80% of all mucosal maltase activity is accounted for by SI.
Invertases are proposed to be important for the prevention of diseases such as ulcers and intestinal ailments in humans, and in anti-aging and physical rejuvenation processes. Their ability to convert glucose into hydrogen peroxide categorizes them as potential antimicrobial and antioxidant agents, thereby assisting in defense reactions against bacterial infections and gut fermentation by oxidation. It is important to note, however, that these putative mechanisms are derived largely from in-vitro biochemical studies and the evidence in intact human physiology is limited.
Background and condition: Congenital sucrase-isomaltase deficiency is an autosomal recessive inherited disaccharidase deficiency characterized by chronic osmotic diarrhea. CSID is an autosomal recessive human intestinal disorder clinically characterized by fermentative diarrhea, abdominal pain, and cramps upon ingestion of sugar. Historically considered a rare condition affecting infants with chronic diarrhea as exposure to dietary sucrose begins, growing evidence suggests that individuals with SI variants may present later in life, with symptoms overlapping with those of irritable bowel syndrome.
Pharmaceutical invertase (sacrosidase): Sucraid (sacrosidase) is the only FDA-approved enzyme replacement therapy indicated for the treatment of sucrase deficiency, which is part of CSID, in adult and pediatric patients 5 months of age and older. It provides a substitute for the sucrase enzyme in the small intestine that is missing or not working in people who have CSID.
Clinical evidence: Six cases of congenital SI deficiency treated with Sucraid (sacrosidase, a yeast-derived enzyme that facilitates sucrose digestion) were described in a published case series. Typical presenting symptoms were watery diarrhoea, abdominal pain and bloating, sometimes noticeably worse after ingestion of fruit. All six patients showed little improvement following advice regarding dietary management, but experienced a marked reduction in symptoms with sacrosidase administration; no adverse events were reported. Sacrosidase was concluded to be an effective and well-tolerated treatment for patients with congenital SI deficiency.
In both pivotal clinical trials, pediatric patients showed a marked decrease in breath hydrogen output when they received sacrosidase in comparison to placebo. Sucraid has been reported to be 81% effective in treating patients with CSID when used appropriately.
Dosage used in clinical studies (sacrosidase/Sucraid): The recommended dosage established in clinical trials is: for patients up to 15 kg — 1 mL (8,500 international units) per meal or snack; for patients over 15 kg — 2 mL (17,000 international units) per meal or snack. Half the dose should be administered at the beginning of the meal or snack and the remainder during the meal or snack.
Limitations: The effects of Sucraid have not been evaluated in patients with secondary (acquired) sucrase deficiency. Clinical trials of Sucraid did not include patients 65 years of age and older to determine if they respond differently from younger adult patients. Sucraid does not break down some sugars that come from the digestion of starch; patients may need to restrict the amount of starch in their diet.
Evidence strength: For the treatment of CSID specifically, sacrosidase (yeast-derived invertase/sucrase) has strong clinical evidence supporting its efficacy, sufficient for FDA approval. This constitutes the highest level of evidence for any application of invertase in human health.
Through its contributions to digestion, invertase may reduce digestive discomfort such as bloating, gas, and cramping associated with sugar malabsorption. Invertase is naturally produced in the small intestine of humans, however as we age invertase enzyme action decreases. This can lead to reduced digestive efficiency and poorer nutrient absorption, meaning that supplementing this enzyme may become increasingly beneficial with age. These claims, however, have limited formal clinical trial support in healthy populations without diagnosed enzyme deficiencies.
Invertase has gained importance in integrative digestive health, where it is combined with enzymes like amylase, lactase, cellulase, and lipase to provide comprehensive support for carbohydrate digestion and nutrient bioavailability.
Evidence strength: Evidence for invertase supplementation in general digestive health (in the absence of CSID) is primarily mechanistic and theoretical. No large-scale, controlled human clinical trials specifically examining invertase supplementation as a standalone intervention in healthy adults have been identified in the peer-reviewed literature.
More efficient sucrose digestion may help to maintain healthy and balanced blood sugar levels. One study found that enzymatic treatment of apple juice with invertase, glucose oxidase, and catalase led to its sugar content being reduced by 21%, as well as a significant reduction in glycaemic load, indicating a reduced increase in blood sugar levels following consumption.
Evidence strength: The evidence for invertase affecting blood glucose in humans is very preliminary. The one cited study involved enzymatic pre-treatment of a beverage, not oral invertase supplementation in human subjects. No controlled human clinical trials specifically examining this outcome have been identified. This area requires further investigation.
Growing evidence suggests that individuals with sucrase-isomaltase (SI) genetic variants may present later in life, with symptoms overlapping with those of irritable bowel syndrome. Treatment of a person suffering from irritable bowel syndrome may be performed by administration of an invertase-containing preparation prior to or with the consumption of a food product. This avenue of research — whether subclinical SI deficiency contributes to IBS-like symptoms and whether invertase supplementation alleviates them — is emerging but not yet conclusively resolved.
Evidence strength: Preliminary. Clinical studies exploring the overlap between SI genetic variants and IBS are in progress, and some clinical trials with sacrosidase in this population have been initiated (e.g., NCT05480761 enrolled 312 subjects). Definitive conclusions cannot yet be drawn from the existing literature.
A patent-based invention described a composition for cleaning teeth and oral cavities containing invertase as an active ingredient, based on the premise that carbohydrates in food residue can be decomposed by acid-producing bacteria into lactic acid, promoting decalcification of dental tissues and dental caries, and that one constituent of dental plaque — dextran — plays a role in the formation and adhesion of dental plaque. It was found that invertase exerts a biological activity in diminishing the formation of dental plaque in the oral cavity.
Evidence strength: Very preliminary; based on patent literature rather than published clinical trials. No peer-reviewed controlled trials in humans were identified for this application.
The proposed ability of invertases to convert glucose into hydrogen peroxide categorizes them as potential antimicrobial and antioxidant agents, assisting in defense reactions against bacterial infections and gut fermentation by oxidation. These proposed mechanisms have been described in the context of biochemical reviews but no dedicated human clinical trials specifically testing invertase as an antimicrobial or antioxidant supplement in humans were identified in the peer-reviewed literature.
Evidence strength: Highly preliminary; primarily theoretical and based on in-vitro biochemical rationale. Human clinical evidence is absent for these specific properties.
Systemic enzyme therapy — the oral administration of mixtures of hydrolytic enzymes — has a research history in Europe, particularly in Germany. European researchers have reported that enzyme therapy can reduce the adverse effects caused by radiotherapy and chemotherapy. However, the evidence specifically and uniquely attributable to invertase within these multi-enzyme preparations is extremely difficult to isolate. Most clinical research in systemic enzyme therapy has been conducted with protease-containing mixtures (e.g., Wobenzym), and invertase has not been the subject of standalone anti-inflammatory clinical trials.
Evidence strength: The anti-inflammatory claims for invertase specifically are not supported by human clinical trials dedicated to this enzyme. The broader enzyme therapy literature concerns primarily proteolytic enzymes, not invertase.
The chemical name of the active ingredient in Sucraid is β,D-fructofuranoside fructohydrolase; the enzyme is derived from baker's yeast (Saccharomyces cerevisiae) by enzymatic digestion with papain. Each milliliter of Sucraid contains 8,500 International Units (IU) of the enzyme sacrosidase.
Documented clinical dosing: for patients up to 15 kg — 1 mL (8,500 IU) per meal or snack; for patients over 15 kg — 2 mL (17,000 IU) per meal or snack. Half the dose should be administered at the beginning of the meal or snack and the remainder during the meal or snack.
Each dose of Sucraid should be mixed in 4 ounces (120 mL) of water, milk, or infant formula. Sucraid should not be mixed or consumed with fruit juice. The product should not be warmed or heated before or after addition.
Digestive enzyme supplements come in the form of capsules, chewable pills, or packets, and may contain one single type of enzyme or a combination of various enzymes. A medicament and dietary supplement containing invertase may be prepared in any suitable form, such as a solid form like a tablet or pill, or a liquid form. Invertase in dietary supplements is typically measured in Sumner Units (SU) per serving, with typical supplement formulations listing activities in the range of hundreds to thousands of SU per dose; however, specific dosage data for non-pharmaceutical invertase supplements from controlled clinical trials have not been identified in the peer-reviewed literature.
Over-the-counter enzyme supplements are regulated as food, so there is much less standardization and quality control in terms of ingredients. The source and dose of an active ingredient — or whether the product even actually contains the active ingredient — are uncertain. The supplements also tend to have less of the active ingredient than prescription products.
An overdose of sacrosidase is not likely to produce any symptoms. In clinical studies of sacrosidase, the adverse experiences noted were: abdominal pain, vomiting, nausea, diarrhea, constipation, insomnia, headache, nervousness, and dehydration.
Sucraid is contraindicated in patients known to be hypersensitive to yeast, yeast products, glycerin (glycerol), or papain. Severe hypersensitivity reactions, including wheezing, rash, and pruritis, have been reported with administration of Sucraid. Sucraid contains papain, which is associated with hypersensitivity reactions. A pediatric patient in the clinical trials experienced a hypersensitivity reaction of severe wheezing that required hospitalization.
Patients should inform their doctor if they are allergic to, have ever had a reaction to, or have ever had difficulty taking yeast, yeast products, papain, or glycerin (glycerol). Sucraid may cause a serious allergic reaction; if any swelling or difficulty breathing occurs, emergency help should be sought immediately.
Patients with diabetes should inform their doctor, as blood glucose levels may change if they begin taking Sucraid; the doctor will advise whether their diet or diabetes medicines need to be changed.
Sucraid does not break down some sugars that come from the digestion of starch. Patients may need to restrict the amount of starch in their diet, and their doctor will advise accordingly.
Sucraid should be mixed with cold or room temperature water, milk, or infant formula prior to administration. Administration in liquids other than water, milk, or infant formula has not been studied and is not recommended. Sucraid must not be mixed with fruit juice. Heating the enzyme prior to use can reduce its activity; sucrose-inverting enzyme incorporated in foodstuffs or pharmaceutical preparations of low water content or containing no water suffers only a very low loss in activity during customary storage times.
As a pharmaceutical product (sacrosidase/Sucraid), invertase is subject to FDA oversight and has demonstrated safety and efficacy for CSID. The safety and effectiveness of Sucraid for the treatment of sucrase deficiency, which is part of CSID, have been established in pediatric patients aged 5 months and older, supported by evidence from adequate and well-controlled studies. As a dietary supplement ingredient, invertase is regulated under a substantially less rigorous framework. Some supplement products have been found to contain possibly harmful impurities or additives, and the FDA has not reviewed non-prescription digestive enzyme products for safety or effectiveness.
Use of digestive enzymes during pregnancy should be approached with caution if the benefits outweigh the risks; animal studies show risk and human studies are not available, or neither animal nor human studies have been done. Side effects of digestive enzymes during breastfeeding are unknown.
Health conditions that Invertase may help support.
When sucrase/invertase activity is insufficient, undigested sucrose passes to the colon where bacterial fermentation generates gas, osmotic diarrhea, bloating, and abdominal cramps. Sacrosidase (oral yeast-derived sucrase) has been shown in randomized controlled trials to significantly reduce these symptoms. Even in adults without full CSID, sucrose malabsorption is a documented and underrecognized cause of abdominal discomfort.
Invertase (sucrase) hydrolyzes sucrose into glucose and fructose at the small intestinal brush border, directly governing the rate and magnitude of postprandial glucose entry into the bloodstream. Inhibiting invertase activity is recognized as a strategy to blunt postprandial blood glucose rises. Efficient sucrase activity is therefore intrinsically tied to glycemic response after sucrose-containing meals.
Invertase (sucrase) hydrolyzes sucrose into glucose and fructose, supporting digestion of table sugar and sucrose-containing foods. It is a natural brush-border enzyme produced in the small intestine and is included in digestive enzyme supplements to address sucrose intolerance and support carbohydrate digestion. Deficiency causes congenital sucrase-isomaltase deficiency.
Invertase cleaves sucrose into glucose and fructose, the two monosaccharides that are absorbed in the small intestine and directly enter energy metabolism. Without adequate sucrase/invertase activity, sucrose cannot be converted to usable fuel. This enzymatic step is physiologically essential for deriving energy from sucrose-containing foods.
Sucrose intolerance arising from sucrase-isomaltase deficiency is a clinically recognized food sensitivity, with sucrase-replacing enzyme (sacrosidase, derived from yeast invertase) being the only FDA-approved pharmacological treatment. Clinical trials confirm that oral sacrosidase eliminates gastrointestinal symptoms in approximately 81% of affected patients consuming a normal diet. Sucrose intolerance is underdiagnosed and may underlie a significant proportion of IBS-like presentations.
Undigested sucrose reaching the colon is fermented by gut bacteria, shifting microbial community composition and generating excess gas. An enzyme blend containing invertase has been studied in vitro for its ability to pre-digest sucrose-containing FODMAPs, reducing colonic fermentation substrate available to the microbiome. Efficient proximal sucrose digestion by invertase therefore helps prevent dysbiotic fermentation patterns in the colon.
Body systems that Invertase may help support.
Go back